VistaPharm Recalls Nystatin Oral Suspension Due to Impurity Peak
VistaPharm is recalling Nystatin Oral Suspension cups because an impurity peak exceeded approved specifications. The recall covers 380,700 cups distributed in the United States and Puerto Rico.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classifies this as a Class III recall, which is defined as unlikely to cause adverse health consequences. The source text does not report any illnesses or injuries.
Plain-English summary
VistaPharm, Inc. is recalling Nystatin Oral Suspension, USP 500,000 units/5mL Cup, which delivers 5 mL. The product is prescription-only and was manufactured in Largo, FL. The recall affects 380,700 cups distributed in the United States, including Puerto Rico.
The recall was initiated due to failed impurities and degradation products. Specifically, the source text notes the presence of an impurity peak that exceeds the approved specification. The affected lots are 619800 (Exp. 12/31/2020), 626200 (Exp. 01/31/2021), 619800X (Exp. 12/31/2020), and 626200X (Exp. 01/31/2021).
The U.S. Food and Drug Administration classifies this as a Class III recall. Consumers and healthcare providers should check their inventory for the specific NDCs 66689-037-50, 66689-037-01, and 66689-037-99 and the lot numbers listed above.
The recalled product
- Product
- Nystatin Oral Suspension, USP 500,000 units/5mL Cup, Delivers 5 mL, Rx Only, Manufactured by: VistaPharm, Largo, FL 33771, a) NDC 66689-037-50 (individual cup NDC: 66689-037-01); b) 66689-037-99.
- Manufacturer
- VistaPharm, Inc.
- Category
- Drug — Antifungal
- Hazard
- Affected units
- 380,700
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: a) 619800
- Exp. 12/31/2020
- 626200
- Exp. 01/31/2021
- b) 619800X
- 626200X
- Exp. 01/31/2021.
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 2 recalled by VistaPharm, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · VistaPharm, Inc.
See all →- ModeratePrescription pyridostigmine bromide oral solution recalled for out-of-specification preservative
FDA (Drugs) · 2022-11-02
- ModerateClobazam Oral Suspension Recalled for Failed Stability Specifications
FDA (Drugs) · 2022-01-26
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity
FDA (Drugs) · 2020-10-14
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Exceeding Specifications
FDA (Drugs) · 2020-07-15
- LowVistaPharm Recalls Nystatin Oral Suspension Due to Impurity Failures
FDA (Drugs) · 2018-12-26
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17